name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.A-3T	c.A-3T				28271	N	intergenic		18451	3947.0	20092						0	T=18450	18450	T	A						False	BA.1.15, BA.1.9, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
c.C-13A	c.C-13A				29545	ORF10	intergenic		2	2.0	20092						1	A=1	1	A	C						False	BA.1.1.17	BA.1.1.17=False	VOC		26-Nov-2021	24-Nov-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		20072	3949.0	20092						0	T=20072	20072	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
c.C-44T	c.C-44T				222	orf1ab	5' UTR		8	8.0	20092						7	T=1	1	T	C						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
c.C-5T	c.C-5T				27389	ORF7a	intergenic		5	5.0	20092						4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
c.C-87T	c.C-87T				27807	ORF8	intergenic		20080	3949.0	20092						0	T=20080	20080	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
c.CGAGGCCACGCGGAGTACGATCGAGTG29733C	c.*4350_*4375delGAGGCCACGCGGAGTACGATCGAGTG				29733	intergenic	Stem-loop,3' UTR		1512	1103.0	20092						1	C=1508	1508	C	CGAGGCCACGCGGAGTACGATCGAGTG						False	BA.2.32, BA.2.26, BA.2.11, BA.2.12, BA.2.7, BA.2.9, BA.2.23, BA.2.3.2, BA.2.16, BA.2.21, BA.2.20, BA.2.3, BA.2, BA.2.3.4, BA.2.10, BA.2.1	BA.2.21=True, BA.2.20=True, BA.2.1=True, BA.2.3.4=True, BA.2.12=True, BA.2.7=True, BA.2=True, BA.2.26=True, BA.2.10=True, BA.2.23=True, BA.2.3.2=True, BA.2.11=True, BA.2.32=True, BA.2.3=True, BA.2.16=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
c.G-132T	c.G-132T				27762	ORF8	intergenic		8	8.0	20092						0	T=8	8	T	G						False	BA.1.21	BA.1.21=True	VOC		26-Nov-2021	24-Nov-2021
c.G29755C	c.G*4371C				29755	intergenic	Stem-loop,3' UTR		21	26.0	20092						11	C=10	10	C	G						False	BA.1.1.15	BA.1.1.15=False	VOC		26-Nov-2021	24-Nov-2021
c.G29781T	c.G*4397T				29781	intergenic	3' UTR		3	49.0	20092						2	T=1	1	T	G						False	BA.1.1.2	BA.1.1.2=False	VOC		26-Nov-2021	24-Nov-2021
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		2870	2238.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=2870	2870	G	GTCTGGTTTT						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.A103P	c.G307C	p.A103P			25699	ORF3a	ORF3a	MISSENSE	89	89.0	20092						58	C=31	31	C	G						False	BA.1.14	BA.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.A1072A	c.A3216G	p.A1072A			3481	orf1ab	ORF1ab	SILENT	92	92.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=92	92	G	A						False	BA.1.3	BA.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.A134A	c.A402G	p.A134A			28675	N	N	SILENT	73	78.0	20092						60	G=13	13	G	A						False	BA.1.13	BA.1.13=False	VOC		26-Nov-2021	24-Nov-2021
p.A1352A	c.C4056T	p.A1352A			4321	orf1ab	ORF1ab	SILENT	2786	1119.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2786	2786	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.A1707A	c.T5121G	p.A1707A			5386	orf1ab	ORF1ab	SILENT	17302	2830.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=17301	17301	G	T						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.A2033V	c.C6098T	p.A2033V			6363	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=1	1	T	C						False	BA.1.9	BA.1.9=True	VOC		26-Nov-2021	24-Nov-2021
p.A2554V	c.C7661T	p.A2554V			7926	orf1ab	ORF1ab	MISSENSE	101	101.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=101	101	T	C						False	BA.1.1.18	BA.1.1.18=True	VOC		26-Nov-2021	24-Nov-2021
p.A260A	c.A780G	p.A260A			1045	orf1ab	ORF1ab	SILENT	8	8.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	2	G=6	6	G	A						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.A2710T	c.G8128A	p.A2710T			8393	orf1ab	ORF1ab	MISSENSE	17303	2830.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=17303	17303	A	G						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.A2909V	c.C8726T	p.A2909V			8991	orf1ab	ORF1ab	MISSENSE	439	470.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=439	439	T	C						False	BA.2.3, BA.2.3.4, BA.2.3.2	BA.2.3=True, BA.2.3.2=True, BA.2.3.4=True	VOC		26-Nov-2021	24-Nov-2021
p.A5026A	c.C15078T	p.A5026A			15342	orf1ab	ORF1ab	SILENT	8	8.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	7	T=1	1	T	C						False	BA.1.21	BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.A50V	c.C149T	p.A50V			28422	N	N	MISSENSE	1	1.0	20092						0	T=1	1	T	C						False	BA.2.11	BA.2.11=True	VOC		26-Nov-2021	24-Nov-2021
p.A516V	c.C1547T	p.A516V			1812	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=1	1	T	C						False	BA.1.14.2	BA.1.14.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A5660S	c.G16978T	p.A5660S			17242	orf1ab	ORF1ab	MISSENSE	12	12.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	2	T=10	10	T	G						False	BA.2.23	BA.2.23=True	VOC		26-Nov-2021	24-Nov-2021
p.A566V	c.C1697T	p.A566V			1962	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=1	1	T	C						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.A5833V	c.C17498T	p.A5833V			17762	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.A5922V	c.C17765T	p.A5922V			18029	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=2	2	T	C						False	BA.2.9.2	BA.2.9.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A6150A	c.C18450T	p.A6150A			18714	orf1ab	ORF1ab	SILENT	2	2.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	T=1	1	T	C						False	BA.1.10	BA.1.10=False	VOC		26-Nov-2021	24-Nov-2021
p.A63T	c.G187A	p.A63T			26709	M	M	MISSENSE	20084	3949.0	20092	caution	ambiguous,amended				4	A=20080	20080	A	G						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.A66S	c.G196T	p.A66S			27589	ORF7a	ORF7a	MISSENSE	3	3.0	20092						0	T=3	3	T	G						False	BA.2.32	BA.2.32=True	VOC		26-Nov-2021	24-Nov-2021
p.A6802A	c.G20406A	p.A6802A			20670	orf1ab	ORF1ab	SILENT	83	83.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	74	A=9	9	A	G						False	BA.2.3.4	BA.2.3.4=False	VOC		26-Nov-2021	24-Nov-2021
p.A698V	c.C2093T	p.A698V			2358	orf1ab	ORF1ab	MISSENSE	273	273.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	198	T=75	75	T	C						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	2018	0.0	20092						0	T=2018	2018	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	2018	0.0	20092						0	T=2018	2018	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	2018	0.0	20092						0	T=2018	2018	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	2018	0.0	20092						0	T=2018	2018	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	2018	0.0	20092						0	T=2018	2018	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) 	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.A735A	c.C2205T	p.A735A			2470	orf1ab	ORF1ab	SILENT	9786	1775.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	432	T=9354	9354	T	C						False	BA.1.1.18, BA.1.1.16, BA.1.1.7, BA.1.1.11, BA.1.1.13, BA.1.1.6, BA.1.1.8, BA.1.1.10, BA.1.1, BA.1.1.17, BA.1.1.2, BA.1.1.14, BA.1.1.15	BA.1.1.6=True, BA.1.1.7=True, BA.1.1=True, BA.1.1.18=True, BA.1.1.10=True, BA.1.1.2=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.1.11=True, BA.1.1.14=True, BA.1.1.15=True, BA.1.1.17=True, BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.A831V	c.C2492T	p.A831V			24054	S	S	MISSENSE	2	2.0	20092						0	T=2	2	T	C	antibody epitope effects	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistent to neutralizing mAb B38	False	BA.1.5	BA.1.5=True	VOC		26-Nov-2021	24-Nov-2021
p.A831V	c.C2492T	p.A831V			24054	S	S	MISSENSE	2	2.0	20092						0	T=2	2	T	C	convalescent plasma escape	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)	False	BA.1.5	BA.1.5=True	VOC		26-Nov-2021	24-Nov-2021
p.A831V	c.C2492T	p.A831V			24054	S	S	MISSENSE	2	2.0	20092						0	T=2	2	T	C	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	BA.1.5	BA.1.5=True	VOC		26-Nov-2021	24-Nov-2021
p.A879V	c.C2636T	p.A879V			24198	S	S	MISSENSE	8	8.0	20092						7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.C19C	c.C57T	p.C19C			29614	ORF10	ORF10	SILENT	5	5.0	20092						4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.C2445C	c.C7335T	p.C2445C			7600	orf1ab	ORF1ab	SILENT	83	83.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=83	83	T	C						False	BA.2.3.4	BA.2.3.4=True	VOC		26-Nov-2021	24-Nov-2021
p.C5898C	c.C17694T	p.C5898C			17958	orf1ab	ORF1ab	SILENT	1	1.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=1	1	T	C						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.C6742F	c.G20225T	p.C6742F			20489	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=1	1	T	G						False	BA.1.9	BA.1.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D1146D	c.C3438T	p.D1146D			25000	S	S	SILENT	19955	3814.0	20092						0	T=19955	19955	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.2.23=True, BA.1.1.11=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D1146Y	c.GAC3436_3438TAT	p.D1146Y			24998	S	S		34	34.0	20092						0	TAT=4, GAT=30	4,30	TAT,GAT	GAC						False	BA.1.1.1	BA.1.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D147N	c.G439A	p.D147N			704	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	7	A=1	1	A	G						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.D155Y	c.G463T	p.D155Y			25855	ORF3a	ORF3a	MISSENSE	98	98.0	20092						69	T=29	29	T	G	caveolin binding	Gupta et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.26.437194v1		In silico, this mutation is the only one weakening ORF3a's binding affinity for caveolin-1 (essential for entry and endomembrane trafficking of SARS-CoV-2). This mutation is a widespread homoplasy in 20A and 20B lineages.	False	BA.1.18	BA.1.18=False	VOC		26-Nov-2021	24-Nov-2021
p.D156D	c.T468C	p.D156D			733	orf1ab	ORF1ab	SILENT	87	87.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	77	C=10	10	C	T						False	BA.1.1.6	BA.1.1.6=False	VOC		26-Nov-2021	24-Nov-2021
p.D1575D	c.C4725T	p.D1575D			4990	orf1ab	ORF1ab	SILENT	384	384.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	267	T=117	117	T	C						False	BA.2.3	BA.2.3=False	VOC		26-Nov-2021	24-Nov-2021
p.D1625D	c.C4875T	p.D1625D			5140	orf1ab	ORF1ab	SILENT	5	5.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.D203D	c.C609T	p.D203D			874	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	1	T=2	2	T	C						False	BA.2.5, BA.1.9	BA.2.5=False, BA.1.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D2833G	c.A8498G	p.D2833G			8763	orf1ab	ORF1ab	MISSENSE	114	114.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	G=114	114	G	A						False	BA.2.21	BA.2.21=True	VOC		26-Nov-2021	24-Nov-2021
p.D3311D	c.C9933T	p.D3311D			10198	orf1ab	ORF1ab	SILENT	2785	1119.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=2785	2785	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D343G	c.A1028G	p.D343G			29301	N	N	MISSENSE	1474	18.0	20092						1	G=1473	1473	G	A						False	BA.1.15.1, BA.1.15.2, BA.1.15	BA.1.15.1=True, BA.1.15=True, BA.1.15.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D3450D	c.C10350T	p.D3450D			10615	orf1ab	ORF1ab	SILENT	2	2.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	1	T=1	1	T	C						False	BA.1.5	BA.1.5=False	VOC		26-Nov-2021	24-Nov-2021
p.D348H	c.G1042C	p.D348H			29315	N	N	MISSENSE	100	100.0	20092						0	C=100	100	C	G						False	BA.2.20	BA.2.20=True	VOC		26-Nov-2021	24-Nov-2021
p.D3897D	c.C11691T	p.D3897D			11956	orf1ab	ORF1ab	SILENT	6	6.0	20092			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	4	T=2	2	T	C						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.D3G	c.A8G	p.D3G			26530	M	M	MISSENSE	17237	2830.0	20092						5	G=17232	17232	G	A						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D405N	c.G1213A	p.D405N			22775	S	S	MISSENSE	2471	1119.0	20092						1	A=2470	2470	A	G						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D40D	c.C120T	p.D40D			21682	S	S	SILENT	2024	0.0	20092						1489	T=535	535	T	C						False	BA.1.17.2	BA.1.17.2=False	VOC		26-Nov-2021	24-Nov-2021
p.D4586Y	c.G13756T	p.D4586Y			14020	orf1ab	ORF1ab	MISSENSE	101	101.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	90	T=11	11	T	G						False	BA.1.1.18	BA.1.1.18=False	VOC		26-Nov-2021	24-Nov-2021
p.D4813N	c.G14437A	p.D4813N			14701	orf1ab	ORF1ab	MISSENSE	15	15.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	13	A=2	2	A	G						False	BA.1.15.1	BA.1.15.1=False	VOC		26-Nov-2021	24-Nov-2021
p.D4915D	c.T14745C	p.D4915D			15009	orf1ab	ORF1ab	SILENT	8	8.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	C=8	8	C	T						False	BA.2.12.1	BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D5128G	c.A15383G	p.D5128G			15647	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	7	G=1	1	G	A						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.D5130D	c.C15390T	p.D5130D			15654	orf1ab	ORF1ab	SILENT	2	2.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	T=1	1	T	C						False	BA.1.1.8	BA.1.1.8=False	VOC		26-Nov-2021	24-Nov-2021
p.D53D	c.C159T	p.D53D			21721	S	S	SILENT	8	8.0	20092						0	T=8	8	T	C						False	BA.2.12.1	BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2028	0.0	20092						0	G=2028	2028	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	20092						0	G=2	2	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	3	3.0	20092						0	G=3	3	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	BA.2.3.2	BA.2.3.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2028	0.0	20092						0	G=2028	2028	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	20092						0	G=2	2	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	3	3.0	20092						0	G=3	3	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.2.3.2	BA.2.3.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20078	3943.0	20092						0	G=20078	20078	G	A	reinfection	Rani et al. (2021)	https://doi.org/10.1002/jmv.26997	'N440K'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20549	7898.0	20092						0	G=20549	20549	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2028	0.0	20092						0	G=2028	2028	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.17.2	BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H655Y'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'H69del', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20077	3942.0	20092						0	G=20077	20077	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	2	2.0	20092						0	G=2	2	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417T'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	3	3.0	20092						0	G=3	3	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.2.3.2	BA.2.3.2=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	17297	2830.0	20092						0	G=17297	17297	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	20084	3949.0	20092						0	G=20084	20084	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D61D	c.T183C	p.D61D			27384	ORF6	ORF6	SILENT	39	39.0	20092						34	C=5	5	C	T						False	BA.1.19	BA.1.19=False	VOC		26-Nov-2021	24-Nov-2021
p.D61L	c.GAT181_183CTC	p.D61L			27382	ORF6	ORF6		2810	1145.0	20092						23	CTC=2781	2781	CTC	GAT						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.16, BA.2.1, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.1.1.15, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.1.1.15=False, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.D6584D	c.C19752T	p.D6584D			20016	orf1ab	ORF1ab	SILENT	1	1.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=1	1	T	C						False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.D69D	c.C207T	p.D69D			27600	ORF7a	ORF7a	SILENT	89	89.0	20092						72	T=17	17	T	C						False	BA.1.14	BA.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.D979D	c.T2937C	p.D979D			24499	S	S	SILENT	3	3.0	20092						2	C=1	1	C	T						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.D992D	c.C2976T	p.D992D			3241	orf1ab	ORF1ab	SILENT	2032	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1453	T=579	579	T	C						False	BA.1.21, BA.1.17.2	BA.1.17.2=False, BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.DRYP6315EGCH	c.TAGATATCC18945_18953GGGGTGTCA	p.DRYP6315EGCH			19209	orf1ab	ORF1ab		1	1.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	GGGGTGTCA=1	1	GGGGTGTCA	TAGATATCC						False	BA.2.2	BA.2.2=True	VOC		26-Nov-2021	24-Nov-2021
p.E235K	c.G703A	p.E235K			968	orf1ab	ORF1ab	MISSENSE	12	12.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	6	A=6	6	A	G						False	BA.2.23	BA.2.23=False	VOC		26-Nov-2021	24-Nov-2021
p.E309Q	c.G925C	p.E309Q			22487	S	S	MISSENSE	1	1.0	20092						0	C=1	1	C	G						False	BA.1.12	BA.1.12=True	VOC		26-Nov-2021	24-Nov-2021
p.E31_S33del	c.89_97delGAGAACGCA	p.E31_S33del			28361	N	N		19841	3949.0	20092						12	G=19825	19825	G	GGAGAACGCA						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E3965E	c.G11895A	p.E3965E			12160	orf1ab	ORF1ab	SILENT	226	228.0	20092			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	0	A=226	226	A	G						False	BA.2.21	BA.2.21=True	VOC		26-Nov-2021	24-Nov-2021
p.E441E	c.A1323G	p.E441E			1588	orf1ab	ORF1ab	SILENT	89	89.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	72	G=17	17	G	A						False	BA.1.14	BA.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	monoclonal antibody serial passage escape	Starr et al. (2020)	https://doi.org/10.1101/2020.11.30.405472		"""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"""	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E484A	c.A1451C	p.E484A			23013	S	S	MISSENSE	15654	3946.0	20092						0	C=15653	15653	C	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.	False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E6473K	c.G19417A	p.E6473K			19681	orf1ab	ORF1ab	MISSENSE	83	83.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	74	A=9	9	A	G						False	BA.2.3.4	BA.2.3.4=False	VOC		26-Nov-2021	24-Nov-2021
p.E6597E	c.A19791G	p.E6597E			20055	orf1ab	ORF1ab	SILENT	2786	1119.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	G=2778	2778	G	A						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.E952K	c.G2854A	p.E952K			3119	orf1ab	ORF1ab	MISSENSE	463	465.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	261	A=202	202	A	G						False	BA.1.1.10	BA.1.1.10=False	VOC		26-Nov-2021	24-Nov-2021
p.F110F	c.C330T	p.F110F			28603	N	N	SILENT	39	39.0	20092						26	T=13	13	T	C						False	BA.1.19	BA.1.19=False	VOC		26-Nov-2021	24-Nov-2021
p.F112F	c.C336T	p.F112F			26858	M	M	SILENT	2784	1119.0	20092						4	T=2780	2780	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.F1544F	c.C4632T	p.F1544F			4897	orf1ab	ORF1ab	SILENT	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=1	1	T	C						False	BA.2.16	BA.2.16=False	VOC		26-Nov-2021	24-Nov-2021
p.F3018F	c.C9054T	p.F3018F			9319	orf1ab	ORF1ab	SILENT	1449	2.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	1281	T=168	168	T	C						False	BA.1.10, BA.1.15	BA.1.10=False, BA.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.F346F	c.C1038T	p.F346F			29311	N	N	SILENT	2	2.0	20092						1	T=1	1	T	C						False	BA.1.1.8	BA.1.1.8=False	VOC		26-Nov-2021	24-Nov-2021
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		2786	1119.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=2786	2786	G	GTCTGGTTTT						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.F4F	c.C12T	p.F4F			26256	E	E	SILENT	26	26.0	20092						23	T=3	3	T	C						False	BA.1.1.15	BA.1.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.F562F	c.C1686T	p.F562F			23248	S	S	SILENT	2	2.0	20092						0	T=2	2	T	C						False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.F6251F	c.C18753T	p.F6251F			19017	orf1ab	ORF1ab	SILENT	78	78.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	61	T=17	17	T	C						False	BA.1.13	BA.1.13=False	VOC		26-Nov-2021	24-Nov-2021
p.F87F	c.C261T	p.F87F			27654	ORF7a	ORF7a	SILENT	30	30.0	20092						27	T=3	3	T	C						False	BA.2.12	BA.2.12=False	VOC		26-Nov-2021	24-Nov-2021
p.F8F	c.C24T	p.F8F			25416	ORF3a	ORF3a	SILENT	1819	152.0	20092						1031	T=788	788	T	C						False	BA.2.21, BA.2.12, BA.2.12.1, BA.2	BA.2.12=True, BA.2.21=True, BA.2.12.1=True, BA.2=False	VOC		26-Nov-2021	24-Nov-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	20092	3949.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=20092	20092	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G100G	c.C300T	p.G100G			25692	ORF3a	ORF3a	SILENT	101	101.0	20092						89	T=12	12	T	C						False	BA.1.1.18	BA.1.1.18=False	VOC		26-Nov-2021	24-Nov-2021
p.G1073R	c.G3217A	p.G1073R			3482	orf1ab	ORF1ab	MISSENSE	103	114.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=103	103	A	G						False	BA.2.21	BA.2.21=True	VOC		26-Nov-2021	24-Nov-2021
p.G1073V	c.G3218T	p.G1073V			3483	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	T=1	1	T	G						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.G1101D	c.G3302A	p.G1101D			3567	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	A=1	1	A	G						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.G1155C	c.G3463T	p.G1155C			3728	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2	2	T	G						False	BA.2.9.2	BA.2.9.2=True	VOC		26-Nov-2021	24-Nov-2021
p.G124S	c.G370A	p.G124S			28643	N	N	MISSENSE	1	1.0	20092						0	A=1	1	A	G						False	BA.1.9	BA.1.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G1307S	c.G3919A	p.G1307S			4184	orf1ab	ORF1ab	MISSENSE	2787	1119.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=2787	2787	A	G						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G1369G	c.A4107C	p.G1369G			4372	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	C=1	1	C	A						False	BA.2.32	BA.2.32=False	VOC		26-Nov-2021	24-Nov-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	2785	1119.0	20092	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	A=2785	2785	A	G	monoclonal antibody serial passage escape	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333	False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G142D	c.G425A	p.G142D			21987	S	S	MISSENSE	2785	1119.0	20092	mask	amplicon_drop_or_primer_artefact,back_to_ref				0	A=2785	2785	A	G	monoclonal antibody serial passage escape	Suryadevara et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1		Selected twice in passage with mAb COV2-2489.	False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G142_Y145delinsD	c.425_433delGTGTTTATT	p.G142_Y145delinsD			21986	S	S		17210	2830.0	20092						0	G=17207	17207	G	GGTGTTTATT						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.G18S	c.G52A	p.G18S			28325	N	N	MISSENSE	1	1.0	20092						0	A=1	1	A	G						False	BA.2.34	BA.2.34=True	VOC		26-Nov-2021	24-Nov-2021
p.G2258G	c.C6774T	p.G2258G			7039	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	T=1	1	T	C						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.G243S	c.G727A	p.G243S			29000	N	N	MISSENSE	1	1.0	20092						0	A=1	1	A	G						False	BA.2.34	BA.2.34=True	VOC		26-Nov-2021	24-Nov-2021
p.G339D	c.G1016A	p.G339D			22578	S	S	MISSENSE	19983	3949.0	20092						0	A=19983	19983	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G339D	c.G1016A	p.G339D			22578	S	S	MISSENSE	19983	3949.0	20092						0	A=19983	19983	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.3 fold	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.G3846S	c.G11536A	p.G3846S			11801	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	A=1	1	A	G						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.G440G	c.A1320C	p.G440G			1585	orf1ab	ORF1ab	SILENT	273	273.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	220	C=53	53	C	A						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.G4436S	c.G13306A	p.G4436S			13570	orf1ab	ORF1ab	MISSENSE	24	26.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	9	A=15	15	A	G						False	BA.1.1.15	BA.1.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.G446S	c.G1336A	p.G446S			22898	S	S	MISSENSE	12963	2825.0	20092						16	A=12947	12947	A	G						False	BA.1.12, BA.1.15, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.G465V	c.G1394T	p.G465V			1659	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=2	2	T	G						False	BA.1.1.17	BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.G496S	c.G1486A	p.G496S			23048	S	S	MISSENSE	17247	2830.0	20092						1	A=17246	17246	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.G82_V84del	c.243_251delTGGTCATGT	p.G82_V84del			507	orf1ab	ORF1ab		2	2.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	1	A=1	1	A	ATGGTCATGT						False	BA.1.1.8	BA.1.1.8=False	VOC		26-Nov-2021	24-Nov-2021
p.G865G	c.T2595C	p.G865G			2860	orf1ab	ORF1ab	SILENT	384	384.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	295	C=89	89	C	T						False	BA.2.3	BA.2.3=False	VOC		26-Nov-2021	24-Nov-2021
p.G894D	c.G2681A	p.G894D			2946	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=1	1	A	G						False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.H125Y	c.C373T	p.H125Y			26895	M	M	MISSENSE	8	8.0	20092						7	T=1	1	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARA_CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BA.1.21	BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.H2794Y	c.C8380T	p.H2794Y			8645	orf1ab	ORF1ab	MISSENSE	92	92.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=92	92	T	C						False	BA.1.3	BA.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.H374Y	c.C1120T	p.H374Y			1385	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	2	T=1	1	T	C						False	BA.2.32	BA.2.32=False	VOC		26-Nov-2021	24-Nov-2021
p.H3895H	c.C11685T	p.H3895H			11950	orf1ab	ORF1ab	SILENT	304	307.0	20092			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	17	T=287	287	T	C						False	BA.1.20	BA.1.20=True	VOC		26-Nov-2021	24-Nov-2021
p.H417Y	c.C1249T	p.H417Y			1514	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.H4747H	c.T14241C	p.H4747H			14505	orf1ab	ORF1ab	SILENT	2	2.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	1	C=1	1	C	T						False	BA.1.1.8	BA.1.1.8=False	VOC		26-Nov-2021	24-Nov-2021
p.H47N	c.C139A	p.H47N			27532	ORF7a	ORF7a	MISSENSE	5	5.0	20092						4	A=1	1	A	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.H5488Y	c.C16462T	p.H5488Y			16726	orf1ab	ORF1ab	MISSENSE	30	30.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	27	T=3	3	T	C						False	BA.2.12	BA.2.12=False	VOC		26-Nov-2021	24-Nov-2021
p.H6020R	c.A18059G	p.H6020R			18323	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	G=1	1	G	A						False	BA.1.14.2	BA.1.14.2=True	VOC		26-Nov-2021	24-Nov-2021
p.H6255H	c.C18765T	p.H6255H			19029	orf1ab	ORF1ab	SILENT	5	5.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	anthropozoonotic events	Esclera et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1		Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H655Y	c.C1963T	p.H655Y			23525	S	S	MISSENSE	20085	3949.0	20092						0	T=20085	20085	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'V70del', 'N501Y'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	'V70del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'V70del', 'N501Y'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'V70del', 'N501Y', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'V70del', 'N501Y', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Kemp et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'V70del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	immunosuppression variant emergence	Kemp et al. (2020)	https://doi.org/10.1101/2020.12.14.422555		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'V70del', 'N501Y'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'V70del', 'N501Y'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'V70del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H69del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'V70del'	21762	S	S		17708	5660.0	20092						6	TTA=17695	17695	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'V70del', 'N501Y', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.H78Y	c.C232T	p.H78Y			25624	ORF3a	ORF3a	MISSENSE	274	275.0	20092						0	T=274	274	T	C						False	BA.2.9.2, BA.2.9	BA.2.9.2=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.I1081V	c.A3241G	p.I1081V			24803	S	S	MISSENSE	15	15.0	20092						0	G=15	15	G	A						False	BA.1.15.1	BA.1.15.1=True	VOC		26-Nov-2021	24-Nov-2021
p.I1221T	c.T3662C	p.I1221T			25224	S	S	MISSENSE	1	1.0	20092						0	C=1	1	C	T						False	BA.2.2	BA.2.2=True	VOC		26-Nov-2021	24-Nov-2021
p.I3055T	c.T9164C	p.I3055T			9429	orf1ab	ORF1ab	MISSENSE	2959	0.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	2180	C=779	779	C	T						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.I337I	c.C1011T	p.I337I			29284	N	N	SILENT	114	114.0	20092						26	T=88	88	T	C						False	BA.2.21	BA.2.21=True	VOC		26-Nov-2021	24-Nov-2021
p.I3758V	c.A11272G	p.I3758V			11537	orf1ab	ORF1ab	MISSENSE	17304	2830.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=17304	17304	G	A						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.I410I	c.C1230T	p.I410I			22792	S	S	SILENT	222	281.0	20092						2	T=220	220	T	C						False	BA.2.34, BA.2.9.2, BA.2.7, BA.2.9	BA.2.9.2=True, BA.2.7=False, BA.2.9=True, BA.2.34=True	VOC		26-Nov-2021	24-Nov-2021
p.I4205I	c.C12615T	p.I4205I			12880	orf1ab	ORF1ab	SILENT	4810	1801.0	20092			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	1793	T=3017	3017	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.1.17.2, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.1.17.2=False, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.I4615V	c.A13843G	p.I4615V			14107	orf1ab	ORF1ab	MISSENSE	100	100.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	G=100	100	G	A						False	BA.1.1.14	BA.1.1.14=True	VOC		26-Nov-2021	24-Nov-2021
p.I5967V	c.A17899G	p.I5967V			18163	orf1ab	ORF1ab	MISSENSE	20086	3949.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	G=20084	20084	G	A						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.I844I	c.T2532A	p.I844I			24094	S	S	SILENT	89	89.0	20092						58	A=31	31	A	T						False	BA.1.14	BA.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.K1266R	c.A3797G	p.K1266R			25359	S	S	MISSENSE	1	1.0	20092						0	G=1	1	G	A						False	BA.1.14.2	BA.1.14.2=True	VOC		26-Nov-2021	24-Nov-2021
p.K1948E	c.A5842G	p.K1948E			6107	orf1ab	ORF1ab	MISSENSE	30	30.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	25	G=5	5	G	A						False	BA.2.12	BA.2.12=False	VOC		26-Nov-2021	24-Nov-2021
p.K2029R	c.A6086G	p.K2029R			6351	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	G=2	2	G	A						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.K3839K	c.A11517G	p.K3839K			11782	orf1ab	ORF1ab	SILENT	16	16.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	14	G=2	2	G	A						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.1 fold	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	15512	3942.0	20092						7	T=15505	15505	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.25 fold	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 antibody C682	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~16x binding against this isolated mutation. Estesevimab lost ~16x binding against this isolated mutation. m396 lost ~8x binding against this isolated mutation.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K417T	c.AG1250_1251CT	p.K417T			22812	S	S		2	2.0	20092						0	CT=2	2	CT	AG	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type) 	False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.K4900K	c.A14700G	p.K4900K			14964	orf1ab	ORF1ab	SILENT	271	273.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	198	G=73	73	G	A						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.K564N	c.G1692T	p.K564N			1957	orf1ab	ORF1ab	MISSENSE	79	79.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=79	79	T	G						False	BA.1.13, BA.1.13.1	BA.1.13=True, BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.K6958R	c.A20873G	p.K6958R			21137	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	4	G=1	1	G	A						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.K856R	c.A2567G	p.K856R			2832	orf1ab	ORF1ab	MISSENSE	17211	2829.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	G=17209	17209	G	A						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.L106F	c.C316T	p.L106F			25708	ORF3a	ORF3a	MISSENSE	1475	18.0	20092						0	T=1475	1475	T	C						False	BA.1.15.1, BA.1.15.2, BA.1.15	BA.1.15.1=True, BA.1.15=True, BA.1.15.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L139F	c.G417T	p.L139F			28690	N	N	MISSENSE	8	8.0	20092						7	T=1	1	T	G						False	BA.1.21	BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.L15L	c.T43C	p.L15L			27244	ORF6	ORF6	SILENT	1	1.0	20092						0	C=1	1	C	T						False	BA.1.12	BA.1.12=True	VOC		26-Nov-2021	24-Nov-2021
p.L1627L	c.C4879T	p.L1627L			5144	orf1ab	ORF1ab	SILENT	87	87.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=87	87	T	C						False	BA.1.1.6	BA.1.1.6=True	VOC		26-Nov-2021	24-Nov-2021
p.L16L	c.C46T	p.L16L			27247	ORF6	ORF6	SILENT	8	8.0	20092						7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.L2062F	c.C6184T	p.L2062F			6449	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=1	1	T	C						False	BA.1.5	BA.1.5=False	VOC		26-Nov-2021	24-Nov-2021
p.L2146F	c.C6436T	p.L2146F			6701	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.L2343L	c.T7027C	p.L2343L			7292	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	C=1	1	C	T						False	BA.1.15.2	BA.1.15.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L24_A27delinsS	c.71_79delTACCCCCTG	p.L24_A27delinsS			21632	S	S		2787	1119.0	20092						0	T=2787	2787	T	TTACCCCCTG						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.L2503F	c.C7507T	p.L2503F			7772	orf1ab	ORF1ab	MISSENSE	8031	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	6983	T=1048	1048	T	C						False	BA.1.1, BA.1.1.7	BA.1.1=False, BA.1.1.7=False	VOC		26-Nov-2021	24-Nov-2021
p.L27L	c.C81T	p.L27L			346	orf1ab	ORF1ab	SILENT	1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=1	1	T	C						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.L3027F	c.C9079T	p.L3027F			9344	orf1ab	ORF1ab	MISSENSE	2786	1119.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=2786	2786	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.L3198L	c.C9592T	p.L3198L			9857	orf1ab	ORF1ab	SILENT	2957	0.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	2498	T=459	459	T	C						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.L3201F	c.C9601T	p.L3201F			9866	orf1ab	ORF1ab	MISSENSE	2784	1119.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	20	T=2764	2764	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.L3208L	c.A9624G	p.L3208L			9889	orf1ab	ORF1ab	SILENT	2	2.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	1	G=1	1	G	A						False	BA.1.5	BA.1.5=False	VOC		26-Nov-2021	24-Nov-2021
p.L3210F	c.C9628T	p.L3210F			9893	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	2	T=1	1	T	C						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L3290L	c.T9870C	p.L3290L			10135	orf1ab	ORF1ab	SILENT	1474	18.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	1	C=1473	1473	C	T						False	BA.1.15.1, BA.1.15.2, BA.1.15	BA.1.15.1=True, BA.1.15=True, BA.1.15.2=True	VOC		26-Nov-2021	24-Nov-2021
p.L3321L	c.C9963T	p.L3321L			10228	orf1ab	ORF1ab	SILENT	2	2.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=2	2	T	C						False	BA.2.16	BA.2.16=True	VOC		26-Nov-2021	24-Nov-2021
p.L3674_G3676del	c.11018_11026delGTTTGTCTG	p.L3674_G3676del			11282	orf1ab	ORF1ab		17302	2830.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	A=17302	17302	A	AGTTTGTCTG						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.L4386L	c.C13158T	p.L4386L			13423	orf1ab	ORF1ab	SILENT	83	83.0	20092			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	0	T=83	83	T	C						False	BA.2.3.4	BA.2.3.4=True	VOC		26-Nov-2021	24-Nov-2021
p.L452Q	c.T1355A	p.L452Q			22917	S	S	MISSENSE	29	38.0	20092						13	A=16	16	A	T	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.07 fold	False	BA.2.12, BA.2.12.1	BA.2.12=False, BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.L452Q	c.T1355A	p.L452Q			22917	S	S	MISSENSE	29	38.0	20092						13	A=16	16	A	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.27 fold	False	BA.2.12, BA.2.12.1	BA.2.12=False, BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.L5150L	c.C15450T	p.L5150L			15714	orf1ab	ORF1ab	SILENT	2786	1119.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=2786	2786	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.L580F	c.C1738T	p.L580F			2003	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=1	1	T	C						False	BA.2.26	BA.2.26=True	VOC		26-Nov-2021	24-Nov-2021
p.L5932L	c.C17796T	p.L5932L			18060	orf1ab	ORF1ab	SILENT	3	3.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	T=2	2	T	C						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	3	3.0	20092	mask	highly_homoplasic				1	T=2	2	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	3	3.0	20092	mask	highly_homoplasic				1	T=2	2	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L5F	c.C13T	p.L5F			21575	S	S	MISSENSE	3	3.0	20092	mask	highly_homoplasic				1	T=2	2	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L6420L	c.C19260T	p.L6420L			19524	orf1ab	ORF1ab	SILENT	79	79.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	31	T=48	48	T	C						False	BA.2.11, BA.1.13	BA.1.13=False, BA.2.11=True	VOC		26-Nov-2021	24-Nov-2021
p.L642F	c.C1924T	p.L642F			2189	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.L6666L	c.A19998G	p.L6666L			20262	orf1ab	ORF1ab	SILENT	2024	0.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	1609	G=415	415	G	A						False	BA.1.17.2	BA.1.17.2=False	VOC		26-Nov-2021	24-Nov-2021
p.L681F	c.C2041T	p.L681F			2306	orf1ab	ORF1ab	MISSENSE	465	465.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	391	T=74	74	T	C						False	BA.1.1.10	BA.1.1.10=False	VOC		26-Nov-2021	24-Nov-2021
p.L6924F	c.C20770T	p.L6924F			21034	orf1ab	ORF1ab	MISSENSE	39	39.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	0	T=39	39	T	C						False	BA.1.19	BA.1.19=True	VOC		26-Nov-2021	24-Nov-2021
p.L730F	c.C2188T	p.L730F			2453	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=3	3	T	C						False	BA.1.1.7	BA.1.1.7=True	VOC		26-Nov-2021	24-Nov-2021
p.L93L	c.C279T	p.L93L			26801	M	M	SILENT	78	78.0	20092						70	T=8	8	T	C						False	BA.1.13	BA.1.13=False	VOC		26-Nov-2021	24-Nov-2021
p.L981F	c.C2941T	p.L981F			24503	S	S	MISSENSE	17283	2830.0	20092						3	T=17280	17280	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.M153T	c.T458C	p.M153T			22020	S	S	MISSENSE	3	3.0	20092						1	C=2	2	C	T						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.M177I	c.G531C	p.M177I			22093	S	S	MISSENSE	2027	0.0	20092						1819	C=208	208	C	G						False	BA.1.17.2	BA.1.17.2=False	VOC		26-Nov-2021	24-Nov-2021
p.M85del	c.253_255delATG	p.M85del			517	orf1ab	ORF1ab		1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=1	1	T	TATG	IFN activity	Lin et al. (2021)	https://doi.org/10.1016/j.chom.2021.01.015		Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 500-523) was tested in vitro for IFN response.	False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.M85del	c.253_255delATG	p.M85del			517	orf1ab	ORF1ab		1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=1	1	T	TATG	IFN activity	Lin et al. (2021)	https://doi.org/10.1016/j.chom.2021.01.015		Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 509-517) was tested in vitro for IFN response.	False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.M85del	c.253_255delATG	p.M85del			517	orf1ab	ORF1ab		1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=1	1	T	TATG	IFN activity	Lin et al. (2021)	https://doi.org/10.1016/j.chom.2021.01.015		Deletions in the genomic nucleotide 500-523 range are shown in vitro culture to downregulated  interferon A1/2 & B1 expression, and are associated with lower clinical severity of disease (Jan-Mar 2020 in China). variations of deletion in this region are found in separate lineages throughout the globe. This specific deletion (genomic 509-523) was tested in vitro for IFN response.	False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.M85del	c.253_255delATG	p.M85del			517	orf1ab	ORF1ab		1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	T=1	1	T	TATG	immunosuppression variant emergence	Avanzato et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/		Emergent as 22% variant by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.  Variant became 100% in day 70 culture. Variant disappeared after convalescent plasma treatment (day 71) in subsequent patient sample sequencing.	False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.N1172D	c.A3514G	p.N1172D			3779	orf1ab	ORF1ab	MISSENSE	79	79.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	3	G=76	76	G	A						False	BA.1.13, BA.1.13.1	BA.1.13=True, BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N1439N	c.C4317T	p.N1439N			4582	orf1ab	ORF1ab	SILENT	1	1.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=1	1	T	C						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.N148T	c.A443C	p.N148T			22005	S	S	MISSENSE	100	100.0	20092						0	C=100	100	C	A						False	BA.2.20	BA.2.20=True	VOC		26-Nov-2021	24-Nov-2021
p.N1709N	c.C5127T	p.N1709N			5392	orf1ab	ORF1ab	SILENT	98	98.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	87	T=11	11	T	C						False	BA.1.18	BA.1.18=False	VOC		26-Nov-2021	24-Nov-2021
p.N211_L212delinsI	c.632_634delATT	p.N211_L212delinsI			22193	S	S		16668	2830.0	20092						5	A=16662	16662	A	AATT						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N25N	c.C75T	p.N25N			29632	ORF10	ORF10	SILENT	2958	1.0	20092						2441	T=517	517	T	C						False	BA.1, BA.1.16	BA.1=False, BA.1.16=True	VOC		26-Nov-2021	24-Nov-2021
p.N3212N	c.T9636C	p.N3212N			9901	orf1ab	ORF1ab	SILENT	1	1.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	C=1	1	C	T						False	BA.1.13.1	BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N354N	c.C1062T	p.N354N			22624	S	S	SILENT	3	3.0	20092						0	T=3	3	T	C						False	BA.2.32	BA.2.32=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.07 fold	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	antibody epitope effects	Cheng et al. (2021)	https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8		N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	reinfection	Rani et al. (2021)	https://doi.org/10.1002/jmv.26997	'D614G'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	15430	3943.0	20092						4	G=15424	15424	G	T	transmissibility	Tandel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1		The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.	False	BA.1.12, BA.1.15, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N48S	c.A143G	p.N48S			28416	N	N	MISSENSE	1	1.0	20092						0	G=1	1	G	A						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.N4992N	c.C14976T	p.N4992N			15240	orf1ab	ORF1ab	SILENT	17303	2830.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=17303	17303	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'H69del', 'V70del'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del', 'V70del'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20033	3942.0	20092						0	T=20033	20033	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'H69del', 'V70del'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'H69del', 'V70del'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20504	7898.0	20092						0	T=20504	20504	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20033	3942.0	20092						0	T=20033	20033	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20033	3942.0	20092						0	T=20033	20033	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	BA.1.12, BA.1.15, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	20040	3949.0	20092						0	T=20040	20040	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	17253	2830.0	20092						0	T=17253	17253	T	A	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N641S	c.A1922G	p.N641S			23484	S	S	MISSENSE	83	83.0	20092						0	G=83	83	G	A						False	BA.2.3.4	BA.2.3.4=True	VOC		26-Nov-2021	24-Nov-2021
p.N6514S	c.A19541G	p.N6514S			19805	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	G=2	2	G	A						False	BA.2.16	BA.2.16=True	VOC		26-Nov-2021	24-Nov-2021
p.N679K	c.T2037G	p.N679K			23599	S	S	MISSENSE	20038	3949.0	20092						0	G=20038	20038	G	T						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N6853N	c.C20559T	p.N6853N			20823	orf1ab	ORF1ab	SILENT	1	1.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	0	T=1	1	T	C						False	BA.2.34	BA.2.34=True	VOC		26-Nov-2021	24-Nov-2021
p.N6920N	c.T20760C	p.N6920N			21024	orf1ab	ORF1ab	SILENT	8	8.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	7	C=1	1	C	T						False	BA.1.21	BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.N75N	c.C225T	p.N75N			28498	N	N	SILENT	100	100.0	20092						0	T=100	100	T	C						False	BA.2.20	BA.2.20=True	VOC		26-Nov-2021	24-Nov-2021
p.N764K	c.C2292A	p.N764K			23854	S	S	MISSENSE	18885	3949.0	20092						7	A=18878	18878	A	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.N810N	c.C2430T	p.N810N			2695	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=3	3	T	C						False	BA.1.13.1, BA.1.1.8	BA.1.1.8=True, BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.N856K	c.C2568A	p.N856K			24130	S	S	MISSENSE	17278	2830.0	20092						1	A=17277	17277	A	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.N969K	c.T2907A	p.N969K			24469	S	S	MISSENSE	20071	3949.0	20092						0	A=20071	20071	A	T						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P1018S	c.C3052T	p.P1018S			3317	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2	2	T	C						False	BA.2.5	BA.2.5=True	VOC		26-Nov-2021	24-Nov-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	19722	3948.0	20092						20	T=19702	19702	T	C	T cell evasion	de Silva et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1		Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	19722	3948.0	20092						20	T=19702	19702	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P162S	c.C484T	p.P162S			28757	N	N	MISSENSE	87	87.0	20092						2	T=85	85	T	C						False	BA.1.1.6	BA.1.1.6=True	VOC		26-Nov-2021	24-Nov-2021
p.P1640S	c.C4918T	p.P1640S			5183	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2	2	T	C						False	BA.1.1.17	BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P3033P	c.A9099G	p.P3033P			9364	orf1ab	ORF1ab	SILENT	1	1.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	G=1	1	G	A						False	BA.1.13.1	BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.P3395H	c.C10184A	p.P3395H			10449	orf1ab	ORF1ab	MISSENSE	17303	2830.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	A=17303	17303	A	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P3395H	c.GCC10182_10184ACA	p.P3395H			10447	orf1ab	ORF1ab		2787	1119.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	ACA=2787	2787	ACA	GCC						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	20092	3949.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	2	T=20090	20090	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P5310L	c.C15929T	p.P5310L			16193	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.P5377L	c.C16130T	p.P5377L			16394	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.P6609P	c.C19827T	p.P6609P			20091	orf1ab	ORF1ab	SILENT	78	78.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	55	T=23	23	T	C						False	BA.1.13	BA.1.13=False	VOC		26-Nov-2021	24-Nov-2021
p.P67S	c.C199T	p.P67S			28472	N	N	MISSENSE	303	307.0	20092						17	T=286	286	T	C						False	BA.1.20	BA.1.20=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'N501Y'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'V70del', 'N501Y'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	20038	3949.0	20092						0	A=19766, AC=75, AT=194	19766,75,194	A,AC,AT	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	17273	2830.0	20092						0	A=17270	17270	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'V70del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.P6932L	c.C20795T	p.P6932L			21059	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	0	T=1	1	T	C						False	BA.2.11	BA.2.11=True	VOC		26-Nov-2021	24-Nov-2021
p.P971S	c.C2911T	p.P971S			3176	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=1	1	T	C						False	BA.1.5	BA.1.5=False	VOC		26-Nov-2021	24-Nov-2021
p.PR13LC	c.CCC38_40TCT	p.PR13LC			28311	N	N		1	1.0	20092						0	TCT=1	1	TCT	CCC						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.Q1113K	c.C3337A	p.Q1113K			24899	S	S	MISSENSE	114	114.0	20092						88	A=26	26	A	C						False	BA.2.21	BA.2.21=False	VOC		26-Nov-2021	24-Nov-2021
p.Q19E	c.C55G	p.Q19E			26577	M	M	MISSENSE	19973	3949.0	20092						5	G=19965	19965	G	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAbs CB6/LY-CoV16 and LY-CoV555.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Somewhat resistent to some class 1 (Spike 'up') antibodies tested. Mix of non- to strongly resistent in class 2 antibodies tested.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 mAb C627 modestly selected for the emergence of this mutation in vitro.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q493R	c.A1478G	p.Q493R			23040	S	S	MISSENSE	20033	3949.0	20092						9	G=20024	20024	G	A	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q501K	c.C1501A	p.Q501K			1766	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	A=2	2	A	C						False	BA.1.1.8	BA.1.1.8=True	VOC		26-Nov-2021	24-Nov-2021
p.Q5267R	c.A15800G	p.Q5267R			16064	orf1ab	ORF1ab	MISSENSE	34	34.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	G=34	34	G	A						False	BA.1.1.1	BA.1.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Q57H	c.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	100	100.0	20092						83	T=17	17	T	G						False	BA.1.1.14	BA.1.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.Q628K	c.C1882A	p.Q628K			23444	S	S	MISSENSE	3	3.0	20092						0	A=3	3	A	C						False	BA.1.15.2	BA.1.15.2=True	VOC		26-Nov-2021	24-Nov-2021
p.Q954H	c.A2862C	p.Q954H			24424	S	S	MISSENSE	1	1.0	20092						0	C=1	1	C	A						False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.Q954H	c.A2862T	p.Q954H			24424	S	S	MISSENSE	20071	3948.0	20092						0	T=20063	20063	T	A						False	BA.1.12, BA.1.15, BA.1.9, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Q957Q	c.A2871G	p.Q957Q			24433	S	S	SILENT	273	273.0	20092						119	G=154	154	G	A						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.R20R	c.A58C	p.R20R			27259	ORF6	ORF6	SILENT	20084	3949.0	20092						0	C=20084	20084	C	A						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.R214_D215insEPE	c.642_643insGAGCCAGAA	p.R214_D215insEPE			22204	S	S		16573	2830.0	20092						44	TGAGCCAGAA=16519	16519	TGAGCCAGAA	T						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.R2875H	c.G8624A	p.R2875H			8889	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	7	A=1	1	A	G						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.R3451R	c.G10353A	p.R3451R			10618	orf1ab	ORF1ab	SILENT	2	2.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	1	A=1	1	A	G						False	BA.2.5	BA.2.5=False	VOC		26-Nov-2021	24-Nov-2021
p.R346K	c.G1037A	p.R346K			22599	S	S	MISSENSE	9827	1810.0	20092						8	A=9819	9819	A	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.12 fold	False	BA.1.1.18, BA.1.1.16, BA.1.1.11, BA.1.1.13, BA.1.1.6, BA.1.1.3, BA.1.1.8, BA.1.1.14, BA.1.1.10, BA.1.1, BA.1.1.15, BA.1.1.1, BA.1.1.2, BA.1.1.7, BA.1.1.17	BA.1.1.6=True, BA.1.1.7=True, BA.1.1=True, BA.1.1.18=True, BA.1.1.10=True, BA.1.1.2=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.1.11=True, BA.1.1.3=True, BA.1.1.14=True, BA.1.1.15=True, BA.1.1.17=True, BA.1.1.13=True, BA.1.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R346K	c.G1037A	p.R346K			22599	S	S	MISSENSE	9827	1810.0	20092						8	A=9819	9819	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	False	BA.1.1.18, BA.1.1.16, BA.1.1.11, BA.1.1.13, BA.1.1.6, BA.1.1.3, BA.1.1.8, BA.1.1.14, BA.1.1.10, BA.1.1, BA.1.1.15, BA.1.1.1, BA.1.1.2, BA.1.1.7, BA.1.1.17	BA.1.1.6=True, BA.1.1.7=True, BA.1.1=True, BA.1.1.18=True, BA.1.1.10=True, BA.1.1.2=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.1.11=True, BA.1.1.3=True, BA.1.1.14=True, BA.1.1.15=True, BA.1.1.17=True, BA.1.1.13=True, BA.1.1.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R408S	c.A1224C	p.R408S			22786	S	S	MISSENSE	2394	1119.0	20092						0	C=2394	2394	C	A	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.21 fold	False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.R550H	c.G1649A	p.R550H			1914	orf1ab	ORF1ab	MISSENSE	26	26.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	23	A=3	3	A	G						False	BA.1.1.15	BA.1.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.R5716C	c.C17146T	p.R5716C			17410	orf1ab	ORF1ab	MISSENSE	2786	1119.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=2786	2786	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.R6138H	c.G18413A	p.R6138H			18677	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	0	A=1	1	A	G						False	BA.1.13.1	BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.R89K	c.G266A	p.R89K			28539	N	N	MISSENSE	103	103.0	20092						91	A=12	12	A	G						False	BA.1.1.18, BA.1.1.17	BA.1.1.18=False, BA.1.1.17=False	VOC		26-Nov-2021	24-Nov-2021
p.R99H	c.G296A	p.R99H			561	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	0	A=1	1	A	G						False	BA.2.11	BA.2.11=True	VOC		26-Nov-2021	24-Nov-2021
p.RG203KR	c.AGTAGGG604_610TCTAAAC	p.RG203KR			28877	N	N		106	106.0	20092						0	TCTAAAC=10, AGTAAAC=96	10,96	TCTAAAC,AGTAAAC	AGTAGGG						False	BA.2.12.1, BA.1.18	BA.1.18=True, BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		19980	3843.0	20092						0	AAC=19975	19975	AAC	GGG						False	BA.1.12, BA.1.15, BA.1.9, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.3.2=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S135R	c.T405G	p.S135R			670	orf1ab	ORF1ab	MISSENSE	2772	1107.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	6	G=2766	2766	G	T						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S1510S	c.C4530T	p.S1510S			4795	orf1ab	ORF1ab	SILENT	8	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	T=6	6	T	C						False	BA.1.21	BA.1.21=False	VOC		26-Nov-2021	24-Nov-2021
p.S165F	c.C494T	p.S165F			25886	ORF3a	ORF3a	MISSENSE	1432	12.0	20092						1198	T=234	234	T	C						False	BA.1.15, BA.2.23	BA.2.23=True, BA.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.S180N	c.G539A	p.S180N			28812	N	N	MISSENSE	83	83.0	20092						74	A=9	9	A	G						False	BA.2.3.4	BA.2.3.4=False	VOC		26-Nov-2021	24-Nov-2021
p.S2083_L2084delinsI	c.6248_6250delGTT	p.S2083_L2084delinsI			6512	orf1ab	ORF1ab		17290	2830.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=17289	17289	A	AGTT						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.S216S	c.C648T	p.S216S			913	orf1ab	ORF1ab	SILENT	39	39.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	26	T=13	13	T	C						False	BA.1.19	BA.1.19=False	VOC		26-Nov-2021	24-Nov-2021
p.S255F	c.C764T	p.S255F			22326	S	S	MISSENSE	384	384.0	20092						268	T=116	116	T	C	monoclonal antibody serial passage escape	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475 		Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28	False	BA.2.3	BA.2.3=False	VOC		26-Nov-2021	24-Nov-2021
p.S279S	c.C837T	p.S279S			1102	orf1ab	ORF1ab	SILENT	5	5.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.S318L	c.C953T	p.S318L			1218	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	1	T=1	1	T	C						False	BA.1.1.17	BA.1.1.17=False	VOC		26-Nov-2021	24-Nov-2021
p.S3244S	c.A9732T	p.S3244S			9997	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	2	T=1	1	T	A						False	BA.1.15.2	BA.1.15.2=False	VOC		26-Nov-2021	24-Nov-2021
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		2786	1119.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=2786	2786	G	GTCTGGTTTT						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S371F	c.C1112T	p.S371F			22674	S	S	MISSENSE	2694	1119.0	20092						0	T=2694	2694	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S371L	c.TC1111_1112CT	p.S371L			22673	S	S		17203	2830.0	20092						0	CT=17195	17195	CT	TC						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.S373P	c.T1117C	p.S373P			22679	S	S	MISSENSE	19927	3949.0	20092						0	C=19927	19927	C	T	monoclonal antibody serial passage escape	Long et al. (2020)	https://doi.org/10.1128/mBio.02707-20		Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S375F	c.C1124T	p.S375F			22686	S	S	MISSENSE	17226	2830.0	20092						0	T=17226	17226	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.S413R	c.A1237C	p.S413R			29510	N	N	MISSENSE	2786	1119.0	20092						4	C=2782	2782	C	A						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.S479F	c.C1436T	p.S479F			1701	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	4	T=1	1	T	C						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.S5360P	c.T16078C	p.S5360P			16342	orf1ab	ORF1ab	MISSENSE	84	84.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	C=84	84	C	T						False	BA.2.10	BA.2.10=True	VOC		26-Nov-2021	24-Nov-2021
p.S55F	c.C164T	p.S55F			26408	E	E	MISSENSE	3	3.0	20092						0	T=3	3	T	C						False	BA.2.3.2	BA.2.3.2=True	VOC		26-Nov-2021	24-Nov-2021
p.S5792L	c.C17375T	p.S5792L			17639	orf1ab	ORF1ab	MISSENSE	181	181.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	T=181	181	T	C						False	BA.1.12, BA.1.6	BA.1.12=True, BA.1.6=True	VOC		26-Nov-2021	24-Nov-2021
p.S704L	c.C2111T	p.S704L			23673	S	S	MISSENSE	20	39.0	20092						0	T=20	20	T	C						False	BA.2.12.1, BA.2.12, BA.1.9	BA.2.12=True, BA.1.9=True, BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.S83L	c.C248T	p.S83L			27641	ORF7a	ORF7a	MISSENSE	2	2.0	20092						0	T=2	2	T	C						False	BA.2.18	BA.2.18=True	VOC		26-Nov-2021	24-Nov-2021
p.S940F	c.C2819T	p.S940F			24381	S	S	MISSENSE	1	1.0	20092						0	T=1	1	T	C						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.S98F	c.C293T	p.S98F			27686	ORF7a	ORF7a	MISSENSE	1	1.0	20092						0	T=1	1	T	C						False	BA.1.7	BA.1.7=True	VOC		26-Nov-2021	24-Nov-2021
p.ST375FA	c.CCA1124_1126TCG	p.ST375FA			22686	S	S		2691	1119.0	20092						0	TCG=2688	2688	TCG	CCA						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.ST477NK	c.GCAC1430_1433ACAA	p.ST477NK			22992	S	S		15641	3946.0	20092						0	ACAA=15617	15617	ACAA	GCAC						False	BA.1.12, BA.1.15, BA.2.11, BA.2.18, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.2.7, BA.2.3.2, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.1.1.14=True, BA.2.32=True, BA.2.16=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T1000I	c.C2999T	p.T1000I			3264	orf1ab	ORF1ab	MISSENSE	384	384.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	343	T=41	41	T	C						False	BA.2.3	BA.2.3=False	VOC		26-Nov-2021	24-Nov-2021
p.T1238T	c.C3714T	p.T1238T			25276	S	S	SILENT	2	2.0	20092						1	T=1	1	T	C						False	BA.1.10	BA.1.10=False	VOC		26-Nov-2021	24-Nov-2021
p.T135I	c.C404T	p.T135I			28677	N	N	MISSENSE	2	2.0	20092						0	T=2	2	T	C						False	BA.2.16	BA.2.16=True	VOC		26-Nov-2021	24-Nov-2021
p.T1538I	c.C4613T	p.T1538I			4878	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1	T=1	1	T	C						False	BA.1.5	BA.1.5=False	VOC		26-Nov-2021	24-Nov-2021
p.T1543I	c.C4628T	p.T1543I			4893	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=1	1	T	C						False	BA.2.2	BA.2.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T1822I	c.C5465T	p.T1822I			5730	orf1ab	ORF1ab	MISSENSE	98	98.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=98	98	T	C						False	BA.1.18	BA.1.18=True	VOC		26-Nov-2021	24-Nov-2021
p.T19I	c.C56T	p.T19I			21618	S	S	MISSENSE	2782	1119.0	20092						0	T=2782	2782	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T2007I	c.C6020T	p.T2007I			6285	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=2	2	T	C						False	BA.2.9.2	BA.2.9.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T2124I	c.C6371T	p.T2124I			6636	orf1ab	ORF1ab	MISSENSE	5	5.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=5	5	T	C						False	BA.2.7	BA.2.7=True	VOC		26-Nov-2021	24-Nov-2021
p.T2152I	c.C6455T	p.T2152I			6720	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	T=4	4	T	C						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.T223I	c.C668T	p.T223I			26060	ORF3a	ORF3a	MISSENSE	2786	1119.0	20092						4	T=2782	2782	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T229I	c.C686T	p.T229I			26078	ORF3a	ORF3a	MISSENSE	1	1.0	20092						0	T=1	1	T	C						False	BA.1.1.13	BA.1.1.13=True	VOC		26-Nov-2021	24-Nov-2021
p.T240P	c.A718C	p.T240P			22280	S	S	MISSENSE	8	8.0	20092						2	C=6	6	C	A						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.T2825I	c.C8474T	p.T2825I			8739	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=1	1	T	C						False	BA.2.26	BA.2.26=True	VOC		26-Nov-2021	24-Nov-2021
p.T296I	c.C887T	p.T296I			29160	N	N	MISSENSE	2	2.0	20092						0	T=2	2	T	C						False	BA.2.16	BA.2.16=True	VOC		26-Nov-2021	24-Nov-2021
p.T3090I	c.C9269T	p.T3090I			9534	orf1ab	ORF1ab	MISSENSE	2786	1119.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=2786	2786	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T3255I	c.C9764T	p.T3255I			10029	orf1ab	ORF1ab	MISSENSE	20091	3949.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=20091	20091	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T3432S	c.C10295G	p.T3432S			10560	orf1ab	ORF1ab	MISSENSE	49	49.0	20092			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	1	G=48	48	G	C						False	BA.1.1.2	BA.1.1.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T3750I	c.C11249T	p.T3750I			11514	orf1ab	ORF1ab	MISSENSE	546	546.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	446	T=100	100	T	C						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.T3791T	c.T11373C	p.T3791T			11638	orf1ab	ORF1ab	SILENT	26	26.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	23	C=3	3	C	T						False	BA.1.1.15	BA.1.1.15=False	VOC		26-Nov-2021	24-Nov-2021
p.T39I	c.C116T	p.T39I			27509	ORF7a	ORF7a	MISSENSE	2	2.0	20092						1	T=1	1	T	C						False	BA.1.1.8	BA.1.1.8=False	VOC		26-Nov-2021	24-Nov-2021
p.T39R	c.C116G	p.T39R			27509	ORF7a	ORF7a	MISSENSE	937	938.0	20092						0	G=937	937	G	C						False	BA.1.1.16	BA.1.1.16=True	VOC		26-Nov-2021	24-Nov-2021
p.T4083M	c.C12248T	p.T4083M			12513	orf1ab	ORF1ab	MISSENSE	464	465.0	20092			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	0	T=464	464	T	C						False	BA.1.1.10	BA.1.1.10=True	VOC		26-Nov-2021	24-Nov-2021
p.T4087I	c.C12260T	p.T4087I			12525	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	0	T=2	2	T	C						False	BA.2.2	BA.2.2=True	VOC		26-Nov-2021	24-Nov-2021
p.T4174I	c.C12521T	p.T4174I			12786	orf1ab	ORF1ab	MISSENSE	90	90.0	20092			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	0	T=90	90	T	C						False	BA.1.14, BA.1.14.2	BA.1.14.2=True, BA.1.14=True	VOC		26-Nov-2021	24-Nov-2021
p.T4175I	c.C12524T	p.T4175I			12789	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	0	T=8	8	T	C						False	BA.2.1	BA.2.1=True	VOC		26-Nov-2021	24-Nov-2021
p.T4533I	c.C13598T	p.T4533I			13862	orf1ab	ORF1ab	MISSENSE	34	34.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	29	T=5	5	T	C						False	BA.1.1.1	BA.1.1.1=False	VOC		26-Nov-2021	24-Nov-2021
p.T4618M	c.C13853T	p.T4618M			14117	orf1ab	ORF1ab	MISSENSE	332	333.0	20092			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	162	T=170	170	T	C						False	BA.1.20, BA.1.1.15	BA.1.1.15=False, BA.1.20=False	VOC		26-Nov-2021	24-Nov-2021
p.T547K	c.C1640A	p.T547K			23202	S	S	MISSENSE	17278	2830.0	20092						0	A=17278	17278	A	C						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.T609I	c.C1826T	p.T609I			2091	orf1ab	ORF1ab	MISSENSE	8	8.0	20092	mask	highly_ambiguous,homoplasic,narrow_src	nsp2	produced by both pp1a and pp1ab	YP_009725298.1	7	T=1	1	T	C						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.T6131T	c.C18393T	p.T6131T			18657	orf1ab	ORF1ab	SILENT	2	2.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	T=1	1	T	C						False	BA.1.1.17	BA.1.1.17=False	VOC		26-Nov-2021	24-Nov-2021
p.T6297I	c.C18890T	p.T6297I			19154	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	1	T=1	1	T	C						False	BA.2.5	BA.2.5=False	VOC		26-Nov-2021	24-Nov-2021
p.T64T	c.C192T	p.T64T			25584	ORF3a	ORF3a	SILENT	20092	3949.0	20092						0	T=20092	20092	T	C						False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T6564I	c.C19691T	p.T6564I			19955	orf1ab	ORF1ab	MISSENSE	2785	1119.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=2785	2785	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T6833I	c.C20498T	p.T6833I			20762	orf1ab	ORF1ab	MISSENSE	15	15.0	20092			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	13	T=2	2	T	C						False	BA.1.15.1	BA.1.15.1=False	VOC		26-Nov-2021	24-Nov-2021
p.T749T	c.A2247G	p.T749T			2512	orf1ab	ORF1ab	SILENT	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	2	G=1	1	G	A						False	BA.1.1.7	BA.1.1.7=False	VOC		26-Nov-2021	24-Nov-2021
p.T791I	c.C2372T	p.T791I			23934	S	S	MISSENSE	1	1.0	20092						0	T=1	1	T	C						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.T842I	c.C2525T	p.T842I			2790	orf1ab	ORF1ab	MISSENSE	2785	1119.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	T=2783	2783	T	C						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.T89I	c.C266T	p.T89I			25658	ORF3a	ORF3a	MISSENSE	3	3.0	20092						2	T=1	1	T	C						False	BA.2.3.2	BA.2.3.2=False	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	17724	5660.0	20092						6	T=17718	17718	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	17724	5660.0	20092						6	T=17718	17718	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	17724	5660.0	20092						6	T=17718	17718	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.T9I	c.C26T	p.T9I			26270	E	E	MISSENSE	20027	3949.0	20092						2	T=20025	20025	T	C	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.V106V	c.C318T	p.V106V			583	orf1ab	ORF1ab	SILENT	78	78.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	70	T=8	8	T	C						False	BA.1.13	BA.1.13=False	VOC		26-Nov-2021	24-Nov-2021
p.V116M	c.G346A	p.V116M			611	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	7	A=1	1	A	G						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V11V	c.C33T	p.V11V			21595	S	S	SILENT	8957	939.0	20092						4328	T=4629	4629	T	C						False	BA.1.1.13, BA.1.1.16, BA.1.1	BA.1.1.16=True, BA.1.1.13=True, BA.1.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V1264M	c.G3790A	p.V1264M			25352	S	S	MISSENSE	1	1.0	20092						0	A=1	1	A	G						False	BA.1.16	BA.1.16=True	VOC		26-Nov-2021	24-Nov-2021
p.V1750V	c.G5250T	p.V1750V			5515	orf1ab	ORF1ab	SILENT	2959	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	1251	T=1708	1708	T	G						False	BA.1, BA.1.5, BA.1.7	BA.1=False, BA.1.7=True, BA.1.5=True	VOC		26-Nov-2021	24-Nov-2021
p.V1783V	c.T5349C	p.V1783V			5614	orf1ab	ORF1ab	SILENT	5	5.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	4	C=1	1	C	T						False	BA.2.7	BA.2.7=False	VOC		26-Nov-2021	24-Nov-2021
p.V1887I	c.G5659A	p.V1887I			5924	orf1ab	ORF1ab	MISSENSE	2127	101.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	A=2127	2127	A	G						False	BA.1.17.2, BA.1.17	BA.1.17=True, BA.1.17.2=True	VOC		26-Nov-2021	24-Nov-2021
p.V2061I	c.G6181A	p.V2061I			6446	orf1ab	ORF1ab	MISSENSE	8	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	A=1	1	A	G						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V213G	c.T638G	p.V213G			22200	S	S	MISSENSE	2787	1119.0	20092						0	G=2779	2779	G	T						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.V29V	c.T87C	p.V29V			26331	E	E	SILENT	8	8.0	20092						2	C=6	6	C	T						False	BA.2.1	BA.2.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V3053V	c.A9159G	p.V3053V			9424	orf1ab	ORF1ab	SILENT	2741	1119.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	1	G=2740	2740	G	A						False	BA.2.11, BA.2.18, BA.2.21, BA.2, BA.2.9.2, BA.2.3.4, BA.2.10, BA.2.32, BA.2.5, BA.2.9, BA.2.12.1, BA.2.23, BA.2.3, BA.2.20, BA.2.1, BA.2.16, BA.2.12, BA.2.7, BA.2.3.2, BA.2.34, BA.2.26, BA.2.2	BA.2.21=True, BA.2.1=True, BA.2.26=True, BA.2.23=True, BA.2.12.1=True, BA.2.3.2=True, BA.2.32=True, BA.2.16=True, BA.2.9.2=True, BA.2.11=True, BA.2.34=True, BA.2.20=True, BA.2.12=True, BA.2=True, BA.2.10=True, BA.2.3=True, BA.2.18=True, BA.2.3.4=True, BA.2.5=True, BA.2.2=True, BA.2.7=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.V320I	c.G958A	p.V320I			22520	S	S	MISSENSE	3	3.0	20092						0	A=3	3	A	G						False	BA.1.15.2	BA.1.15.2=True	VOC		26-Nov-2021	24-Nov-2021
p.V320V	c.C960T	p.V320V			22522	S	S	SILENT	306	307.0	20092						150	T=156	156	T	C						False	BA.1.20	BA.1.20=False	VOC		26-Nov-2021	24-Nov-2021
p.V32L	c.G94T	p.V32L			27987	ORF8	ORF8	MISSENSE	100	100.0	20092						46	T=54	54	T	G						False	BA.1.1.14	BA.1.1.14=False	VOC		26-Nov-2021	24-Nov-2021
p.V3782I	c.G11344A	p.V3782I			11609	orf1ab	ORF1ab	MISSENSE	2958	0.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	2180	A=778	778	A	G						False	BA.1	BA.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V4057V	c.T12171C	p.V4057V			12436	orf1ab	ORF1ab	SILENT	273	273.0	20092			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	223	C=50	50	C	T						False	BA.2.9	BA.2.9=False	VOC		26-Nov-2021	24-Nov-2021
p.V4310V	c.T12930C	p.V4310V			13195	orf1ab	ORF1ab	SILENT	17304	2830.0	20092			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	14	C=17290	17290	C	T						False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V606F	c.G1816T	p.V606F			2081	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	1	T=2	2	T	G						False	BA.1.1.7	BA.1.1.7=False	VOC		26-Nov-2021	24-Nov-2021
p.V62L	c.G184T	p.V62L			28077	ORF8	ORF8	MISSENSE	2	2.0	20092						1	T=1	1	T	G						False	BA.1.1.17	BA.1.1.17=False	VOC		26-Nov-2021	24-Nov-2021
p.V6362I	c.G19084A	p.V6362I			19348	orf1ab	ORF1ab	MISSENSE	34	34.0	20092			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	29	A=5	5	A	G						False	BA.1.1.1	BA.1.1.1=False	VOC		26-Nov-2021	24-Nov-2021
p.V6474L	c.G19420T	p.V6474L			19684	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	T=1	1	T	G						False	BA.1.13.1	BA.1.13.1=True	VOC		26-Nov-2021	24-Nov-2021
p.V6638A	c.T19913C	p.V6638A			20177	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	C=1	1	C	T						False	BA.1.1.3	BA.1.1.3=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis)."	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped  lentivirus, but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'H69del', 'N501Y'	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	'H69del'	Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del', 'N501Y'	Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x). PG: these effects are laregly missing in the deletion-alone data	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'N501Y', 'P681H'	One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'H69del', 'N501Y', 'P681H'	Slight neutralization improvement on average in 16 health workers' convalescent sera.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Kemp et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	'H69del'	Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del'	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G and this was noticeable in the lack of sera with high neutralizing titer for the viruses  across 10 convalescent sera from April 2020 infectees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	immunosuppression variant emergence	Kemp et al. (2020)	https://doi.org/10.1101/2020.12.14.422555		The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7] Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	symptom prevalence	Snell et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.16.21253377v1	'H69del', 'N501Y'	A higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	symptom prevalence	van Loon et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.15.21255389v1	'H69del', 'N501Y'	"In comparison of B.1.1.7 lineage (193 cases) vs. ""wildtype"" (125) in Berlin Jan 18 to March 29 2021,  significant symptom changes are absent loss of smell/taste (P"	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, moreso than this combination with the addition of P681H.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	Lentiviral pseudotyped with this mutation set from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing significant (40%) increase in infection rate amongst the cells, much more than the effect of  either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect  contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G', 'H69del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V70del	c.CTATACATG200_208TTA	p.A67_V70delinsVI	A67_V70delinsVI	'A67V', 'H69del'	21762	S	S		17245	2830.0	20092						5	TTA=17233	17233	TTA	CTATACATG	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	'H69del', 'N501Y', 'P681H'	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	BA.1.12, BA.1.15, BA.1.9, BA.1.1.8, BA.1.7, BA.1.1.7, BA.1.1.14, BA.1.1.18, BA.1.16, BA.1.10, BA.1.14, BA.1.15.2, BA.1.1.10, BA.1.1.2, BA.1.17, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.1.1.3, BA.1.14.2, BA.1.1, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6	BA.1.17.2=True, BA.1.1.18=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.1.13.1=True, BA.1.1.14=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.1.15.2=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.1.1.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.1.1.13=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.1.1.15=True, BA.1.1.17=True	VOC		26-Nov-2021	24-Nov-2021
p.V781V	c.T2343C	p.V781V			23905	S	S	SILENT	1	1.0	20092						0	C=1	1	C	T						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.V88V	c.A264G	p.V88V			26786	M	M	SILENT	8	8.0	20092						7	G=1	1	G	A						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.W128C	c.G384T	p.W128C			25776	ORF3a	ORF3a	MISSENSE	384	384.0	20092						277	T=107	107	T	G						False	BA.2.3	BA.2.3=False	VOC		26-Nov-2021	24-Nov-2021
p.W2232C	c.G6696T	p.W2232C			6961	orf1ab	ORF1ab	MISSENSE	3	3.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	T=1	1	T	G						False	BA.2.32	BA.2.32=False	VOC		26-Nov-2021	24-Nov-2021
p.Y1174Y	c.C3522T	p.Y1174Y			3787	orf1ab	ORF1ab	SILENT	8	8.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	7	T=1	1	T	C						False	BA.2.12.1	BA.2.12.1=False	VOC		26-Nov-2021	24-Nov-2021
p.Y196Y	c.C588T	p.Y196Y			27110	M	M	SILENT	75	100.0	20092						65	T=10	10	T	C						False	BA.2.20	BA.2.20=False	VOC		26-Nov-2021	24-Nov-2021
p.Y26Y	c.C78T	p.Y26Y			29635	ORF10	ORF10	SILENT	1	1.0	20092						0	T=1	1	T	C						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.Y3074Y	c.C9222T	p.Y3074Y			9487	orf1ab	ORF1ab	SILENT	15	15.0	20092			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	13	T=2	2	T	C						False	BA.1.15.1	BA.1.15.1=False	VOC		26-Nov-2021	24-Nov-2021
p.Y360Y	c.C1080T	p.Y360Y			29353	N	N	SILENT	1	1.0	20092						0	T=1	1	T	C						False	BA.1.1.11	BA.1.1.11=True	VOC		26-Nov-2021	24-Nov-2021
p.Y3803Y	c.C11409T	p.Y3803Y			11674	orf1ab	ORF1ab	SILENT	46	76.0	20092			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	20	T=26	26	T	C						False	BA.2.12, BA.2.12.1	BA.2.12=False, BA.2.12.1=True	VOC		26-Nov-2021	24-Nov-2021
p.Y505H	c.T1513C	p.Y505H			23075	S	S	MISSENSE	20040	3949.0	20092						0	C=20040	20040	C	T	anthropozoonotic events	McAloose et al. (2020)	https://dx.doi.org/10.1128/mBio.02220-20		Observed first in a single tiger (cohort of 5), potential adaptation.	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Y505H	c.T1513C	p.Y505H			23075	S	S	MISSENSE	20040	3949.0	20092						0	C=20040	20040	C	T	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.16 fold	False	BA.1.12, BA.1.15, BA.1.9, BA.2.18, BA.2.11, BA.1.1.8, BA.2.21, BA.2, BA.2.9.2, BA.1.7, BA.2.3.4, BA.2.10, BA.1.1.14, BA.1.1.7, BA.1.1.18, BA.1.16, BA.2.32, BA.2.5, BA.1.10, BA.1.14, BA.1.15.2, BA.2.12.1, BA.2.9, BA.2.23, BA.2.3, BA.1.1.10, BA.2.20, BA.1.1.2, BA.1.17, BA.2.16, BA.2.1, BA.1.13, BA.1.17.2, BA.1, BA.1.19, BA.1.1.6, BA.2.12, BA.1.1.3, BA.1.14.2, BA.2.3.2, BA.2.7, BA.1.1, BA.2.34, BA.1.3, BA.1.1.17, BA.1.1.15, BA.1.18, BA.1.1.16, BA.1.21, BA.1.13.1, BA.1.1.11, BA.2.26, BA.1.1.13, BA.1.15.1, BA.1.20, BA.1.1.1, BA.1.5, BA.1.6, BA.2.2	BA.2.21=True, BA.1.17.2=True, BA.2.1=True, BA.1.1.18=True, BA.2.26=True, BA.1.18=True, BA.1.17=True, BA.1.1.11=True, BA.2.23=True, BA.2.12.1=True, BA.1.13.1=True, BA.1.1.14=True, BA.2.3.2=True, BA.2.16=True, BA.2.32=True, BA.1.1.1=True, BA.1.20=True, BA.1.12=True, BA.1.15.1=True, BA.1.13=True, BA.1.1.2=True, BA.2.9.2=True, BA.1.14=True, BA.1.16=True, BA.1.21=True, BA.2.11=True, BA.1.15.2=True, BA.2.34=True, BA.2.20=True, BA.1.1.6=True, BA.1.19=True, BA.1.3=True, BA.2.12=True, BA.1.1.10=True, BA.2=True, BA.2.10=True, BA.1.9=True, BA.1.14.2=True, BA.1.15=True, BA.2.3=True, BA.2.7=True, BA.1.1.13=True, BA.2.18=True, BA.1.1.7=True, BA.1.1=True, BA.1.5=True, BA.1=True, BA.2.3.4=True, BA.1.6=True, BA.1.7=True, BA.1.1.16=True, BA.1.1.8=True, BA.1.10=True, BA.1.1.3=True, BA.2.5=True, BA.2.2=True, BA.1.1.15=True, BA.1.1.17=True, BA.2.9=True	VOC		26-Nov-2021	24-Nov-2021
p.Y5593C	c.A16778G	p.Y5593C			17042	orf1ab	ORF1ab	MISSENSE	2	2.0	20092			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	G=2	2	G	A						False	BA.1.10	BA.1.10=True	VOC		26-Nov-2021	24-Nov-2021
p.Y947H	c.T2839C	p.Y947H			3104	orf1ab	ORF1ab	MISSENSE	1	1.0	20092			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	C=1	1	C	T						False	BA.1.16	BA.1.16=True	VOC		26-Nov-2021	24-Nov-2021
